These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 28965624)
21. Utility of GATA3, mammaglobin, GCDFP-15, and ER in the detection of intrathoracic metastatic breast carcinoma. Dyhdalo KS; Booth CN; Brainard JA; Croyle MC; Kolosiwsky AM; Goyal A; Gildea TR; Almeida FA; Nassar A; Reynolds JP J Am Soc Cytopathol; 2015; 4(4):218-224. PubMed ID: 31051757 [TBL] [Abstract][Full Text] [Related]
22. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249 [TBL] [Abstract][Full Text] [Related]
23. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642 [TBL] [Abstract][Full Text] [Related]
24. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes. Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285 [TBL] [Abstract][Full Text] [Related]
25. Utility of GATA-3 in the work-Up of breast adenocarcinoma and its differential diagnosis in serous effusions:: A Cell-Block Microarray Study. El Hag MI; Ha J; Farag R; El Hag AM; Michael CW Diagn Cytopathol; 2016 Sep; 44(9):731-6. PubMed ID: 27338760 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic utility and sensitivities of GATA3 antibodies in triple-negative breast cancer. Krings G; Nystrom M; Mehdi I; Vohra P; Chen YY Hum Pathol; 2014 Nov; 45(11):2225-32. PubMed ID: 25150746 [TBL] [Abstract][Full Text] [Related]
27. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors. Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583 [TBL] [Abstract][Full Text] [Related]
28. Expression of mammaglobin and gross cystic disease fluid protein-15 in breast carcinomas. Luo MH; Huang YH; Ni YB; Tsang JY; Chan SK; Shao MM; Tse GM Hum Pathol; 2013 Jul; 44(7):1241-50. PubMed ID: 23332923 [TBL] [Abstract][Full Text] [Related]
29. Strong androgen receptor expression is not useful in distinguishing GATA3 + metastases. Lionti S; La Rocca L; Nunnari CM; Barresi V Pathol Res Pract; 2018 Dec; 214(12):2110-2114. PubMed ID: 30293951 [TBL] [Abstract][Full Text] [Related]
30. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444 [TBL] [Abstract][Full Text] [Related]
31. Utility of mammaglobin and gross cystic disease fluid protein-15 (GCDFP-15) in confirming a breast origin for recurrent tumors. Chia SY; Thike AA; Cheok PY; Tan PH Breast; 2010 Oct; 19(5):355-9. PubMed ID: 20347310 [TBL] [Abstract][Full Text] [Related]
32. Diagnostic utility of mammaglobin and GCDFP-15 in the identification of metastatic breast carcinoma in fluid specimens. Yan Z; Gidley J; Horton D; Roberson J; Eltoum IE; Chhieng DC Diagn Cytopathol; 2009 Jul; 37(7):475-8. PubMed ID: 19217055 [TBL] [Abstract][Full Text] [Related]
33. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781 [TBL] [Abstract][Full Text] [Related]
35. Co-expression and prognostic value of gross cystic disease fluid protein 15 and mammaglobin in primary breast cancer. Fritzsche FR; Thomas A; Winzer KJ; Beyer B; Dankof A; Bellach J; Dahl E; Dietel M; Kristiansen G Histol Histopathol; 2007 Nov; 22(11):1221-30. PubMed ID: 17647195 [TBL] [Abstract][Full Text] [Related]
36. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin. Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362 [TBL] [Abstract][Full Text] [Related]
37. Cytokeratin 7-negative and GATA binding protein 3-negative breast cancers: Clinicopathological features and prognostic significance. Lu S; Yakirevich E; Wang LJ; Resnick MB; Wang Y BMC Cancer; 2019 Nov; 19(1):1085. PubMed ID: 31718619 [TBL] [Abstract][Full Text] [Related]
38. Comparative Sensitivities and Specificities of Antibodies to Breast Markers GCDFP-15, Mammaglobin A, and Different Clones of Antibodies to GATA-3: A Study of 338 Tumors Using Whole Sections. Kandalaft PL; Simon RA; Isacson C; Gown AM Appl Immunohistochem Mol Morphol; 2016 Oct; 24(9):609-614. PubMed ID: 26447897 [TBL] [Abstract][Full Text] [Related]
39. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study. Ordóñez NG; Sahin AA Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068 [TBL] [Abstract][Full Text] [Related]
40. Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple-negative tumours. Provenzano E; Byrne DJ; Russell PA; Wright GM; Generali D; Fox SB Histopathology; 2016 Feb; 68(3):367-77. PubMed ID: 26118394 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]